The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer.
VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer.
Preclinical evaluation of VTX-2337 suggests that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology.
Michael Kamdar, chief business officer of VentiRx, said: “We are delighted to advance the first molecule from our Toll-Like Receptor 8 platform, VTX-2337, into the clinic. This represents a significant milestone for VentiRx and our Toll-Like Receptor efforts as we have rapidly advanced into a clinical development company with a novel molecule that may have broad application in the treatment of cancer.”